On ECHEMI
Home > Drugs > Acute eosinophilic pneumonia
Acute eosinophilic pneumonia
Acute eosinophilic pneumonia (AEP) was first reported in 1989. Because it is different from simple pulmonary eosinophilic infiltration, it has been regarded as an independent clinical disease in recent years.
  • Site of disease:

    lung
  • Infectious :

    Not contagious
  • Frequent population:

    All groups
  • Related symptoms:

    Chest pain shortness of breath hemoptysis with choking cough myalgia cough
  • Concurrent disease:

Related Drugs
Cefepime Hydrochloride for Injection
Indication: This product can be used to treat moderate to severe infections caused by the above-mentioned sensitive bacteria in adults and children aged 2 months to 16 years, including lower respiratory tract infections (pneumonia and bronchitis), simple lower urinary tract infections and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin and soft tissue infections, complicated intra-abdominal infections (including peritonitis and biliary tract infections), obstetrics and gynecology infections, sepsis, and empirical treatment of patients with neutropenia and fever. It can also be used for bacterial cerebrospinal meningitis in children. Bacterial culture and drug sensitivity testing should be performed when bacterial infection is suspected, but because cefepime is a broad-spectrum bactericidal agent for Gram-positive and Gram-negative bacteria, cefepime monotherapy can be started before the results of drug sensitivity tests are known. When mixed anaerobic infections are suspected, it is recommended to use other anti-anaerobic drugs in combination.
Manufacturer:

STAR Pharmaceutical Pte.ltd

Piperacillin Sodium and Tazobactam Sodium for Injection
Indication: This product is suitable for the following moderate and severe infections caused by β-lactamase-producing bacteria that are resistant to piperacillin but sensitive to tazobactam/piperacillin: 1. Appendicitis (with perforation or abscess) and peritonitis caused by piperacillin-resistant, β-lactamase-producing Escherichia coli and Bacteroides (Bacteroides fragilis, Bacteroides ovale, Bacteroides thetaiotaomicron). 2. Uncomplicated and complicated skin and soft tissue infections caused by piperacillin-resistant, β-lactamase-producing Staphylococcus aureus, including cellulitis, skin abscesses, ischemic or diabetic foot infections. 3. Postpartum endometritis or pelvic inflammatory disease caused by piperacillin-resistant, β-lactamase-producing Escherichia coli. 4. Community-acquired pneumonia (moderate only) caused by piperacillin-resistant, β-lactamase-producing Haemophilus influenzae. 5. Moderate to severe hospital-acquired pneumonia (hospital pneumonia) caused by piperacillin-resistant, β-lactamase-producing Staphylococcus aureus.
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.